Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Share-based Compensation (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Share-based Compensation for 3 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 18.45% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, down 2.24% year-over-year, with the annual reading at $8.4 million for FY2025, 2.24% down from the prior year.
  • Share-based Compensation hit $1.8 million in Q4 2025 for Compass Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q2 2025 to a low of $1.2 million in Q3 2025.
  • Historically, Share-based Compensation has averaged $1.9 million across 3 years, with a median of $1.9 million in 2024.
  • Biggest five-year swings in Share-based Compensation: soared 58.09% in 2024 and later tumbled 43.68% in 2025.
  • Year by year, Share-based Compensation stood at $1.6 million in 2023, then surged by 39.88% to $2.2 million in 2024, then dropped by 18.45% to $1.8 million in 2025.
  • Business Quant data shows Share-based Compensation for CMPX at $1.8 million in Q4 2025, $1.2 million in Q3 2025, and $2.8 million in Q2 2025.